Alector, Inc.

NASDAQ:ALEC

Biotechnology

Healthcare
$2.57 +5.13%

+$0.08 today

Market cap
$382.61M
Beta
0.59
P/E (TTM)
-1.4
EPS (TTM)
-$1.13
52W Low $1.09High $3.40

Volume 2.13M

Average 0.65M

ALEC Other Financing Activities

Financing cash flows not reported separately.

Alector, Inc.NASDAQ: ALEC

Other Financing Activities · Q1 FY2026 · quarter ended Mar 2026

Other financing activities outflow grows to $0

Q1 FY2026 other financing activities was $0, compared with $0 a year earlier. Trailing-twelve-month other financing activities was $217K.

Context

  • Other financing activities amounted to 1.0% of revenue in FY2025, unchanged from a year earlier.
  • Other financing activities increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly other financing activities holds near $0 or moves back toward the trailing-twelve-month quarterly average of $54.25K.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0-100.0% QoQ
Last fiscal yearDec 2025
$217K-79.2% YoY
LTMMar 2026
$217K-79.2% YoY
Other Financing Activities past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year-79.2%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Other Financing Activities history

USD · from the cash flow

Latest · FY2025
217K USD
Year-over-year change
-79.2%
4-year CAGR
-70.9%

Other Financing Activities vs competitors

How ALEC compares with its peers on the latest reported figures

  • Peers report in different currencies, so other financing activities is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -79.2% is the 3rd highest of 8, against a peer median of -99.2%.
  • Other financing activities amounts to 1.2% of revenue for ALEC, versus a peer median of 43.9%.
ALEC Competitors
Other Financing Activities for ALEC and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ABOSAcumen Pharmaceuticals, Inc.LTM Mar 2026$35.6M USD+4487.2%——
FATEFate Therapeutics, Inc.LTM Mar 2026$5.49M USD+8.4%—86.9%
MOLNMolecular Partners AGLTM Mar 2026CHF 413.44K CHF-102.6%——
ALECAlector, Inc.LTM Mar 2026$217K USD-79.2%—1.2%
VORVor Biopharma Inc.LTM Mar 2026$184K USD-92.4%——
IRDOpus Genetics, Inc.LTM Mar 2026$112K USD-99.2%—0.9%
PEPGPepGen Inc.LTM Mar 2026$7K USD———
NKTXNkarta, Inc.LTM Mar 2026$0 USD-100.0%——
CRBPCorbus Pharmaceuticals Holdings, Inc.LTM Mar 2026$0 USD-100.0%——
Peer median (excluding ALEC) —-99.2%—43.9%

Competitors are the stored peer set for ALEC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(36.33M)(133.31M)(130.39M)(119.05M)(142.93M)
Depreciation & Amortization8.32M8.47M8.85M8.84M(861K)
Deferred Income Tax00000
Stock-Based Compensation40.79M46.15M42.8M39.46M26.66M
Change in Working Capital283.68M59.53M(90.15M)(146.99M)(74.06M)
Accounts Receivables(7.39M)4.8M2.59M00
Inventory00000
Accounts Payables1.92M(572K)(377K)(1.44M)(524K)
Other Working Capital289.16M55.29M(92.36M)(145.55M)(73.53M)
Other Non-Cash Items2.1M(1.16M)(15.27M)(12.17M)7.16M
Operating Cash Flow298.55M(20.33M)(184.16M)(229.91M)(184.03M)
Capital Expenditures(3.25M)(4.12M)(2.38M)(1.26M)(41K)
Acquisitions (Net)00000
Purchases of Investments(343.4M)(556.9M)(551.73M)(467.74M)(271.88M)
Sales of Investments296.99M402M656.03M576.13M468.52M
Other Investing Activities00000
Investing Cash Flow(49.66M)(159.01M)101.92M107.13M196.6M
Debt Repayment0009.39M0
Common Stock Issued04.51M2.55M71.11M20M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities30.3M001.04M217K
Financing Cash Flow30.3M4.51M2.55M81.54M20.22M
Effect of Forex Changes00000
Net Change in Cash279.18M(174.83M)(79.69M)(41.23M)32.78M
Free Cash Flow295.3M(24.45M)(186.54M)(231.16M)(184.07M)

Alector, Inc.

NASDAQ:ALEC

Intrinsic Alpha fair value

Locked

Current Price

$2.57

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.